ArticlePloS one2026
Ultrasound-triggered doxorubicin targeted delivery for liver cancer treatment: Reduced toxicity and improved efficacy.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer, especially hepatocellular carcinoma (HCC), remains a major global health challenge, causing high mortality worldwide. Conventional chemotherapy often results in severe side effects due to its systemic distribution, which limits its effectiveness in targeting cancer cells specifically. The development of targeted drug delivery systems can enhance the precision and efficacy of chemotherapeutic agents while reducing their side effects. In this context, we used lactobionic acid (LA) as a targeting moiety due to its ability to bind to the asialoglycoprotein receptor (ASGPR), which is highly expressed on the surface of hepatocytes (liver cells). Conjugating lactobionic acid to liposomes creates an efficient delivery system that specifically targets liver cancer cells, thereby ensuring a higher uptake of the drug by these cells. Ultrasound is used to further facilitate drug release by enhancing drug targeting, promoting accumulation at the tumor site, and triggering drug release, thereby making the treatment more effective and less toxic. This study successfully synthesized stable DOX-loaded liposomes conjugated with lactobionic acid (LL) on their surface, with a size range of 89.4 ± 0.9 nm and a polydispersity index of 13.06 ± 3.5. Successful LA-DSPE-PEG-NH2 conjugation to the LL was confirmed via Fourier Transform Infrared spectroscopy. The sulfuric acid colorimetric assay quantified lactobionic acid conjugation as 14 ± 1.35% (w/w), while DOX encapsulation was measured at 40.1 ± 1.6%. LL exhibited strong absorption, fluorescence properties and good stability at 37 ˚C. LL showed controlled release via ultrasound, making it suitable for precise drug delivery. In vitro studies on HepG2 cells confirmed enhanced drug uptake and therapeutic efficacy. The effects of ultrasound-enhanced drug delivery to HepG2 cells demonstrated that the combination of ultrasound and targeted liposomes significantly increased the internalization of the drug (DOX) and triggered apoptosis in HepG2 cells, leading to cell death. Morphological observations on treated cells via phase contrast microscopy supported the signs of apoptosis, indicating LL's potential to target liver cancer cells effectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.